title: Age impact on human papillomavirus vaccination in France in 2014: A study from the National Health Insurance Database.
abstract: BACKGROUND
  Human papillomavirus (HPV) is the main cause of cervical cancer. In France, since March 2007, HPV vaccination has been recommended for girls aged 14, in addition to a catch-up program for girls aged 15 to 23. In October 2012, the target population was changed to 11- to 14-year-old girls. The main objective of the present study was to evaluate the impact of the recommendation change on HPV vaccination coverage and compliance.
  
  
  METHODS
  We conducted a descriptive study of the Échantillon Généraliste des Bénéficiaires (EGB), which is a random 1/97 permanent sample from the French National Health Insurance Database. We focused our analyses on girls aged 11 to 17 years who were covered by the main insurance scheme (which covers 77% of the French population).
  
  
  RESULTS
  We included 16,195 girls in this analysis. At the last update of the database (06/15/2014), 42% of 17-year-old girls had been vaccinated, with more than 50% of them having been vaccinated at age 14. Between January 2012 and June 2014, patients were reimbursed for a total of 7698 doses of the HPV vaccine. During the first trimester of 2013, the number of vaccinated 11- to 13-year-old girls increased, growing by more than 20-fold between the last trimester of 2012 (n=8) and the last trimester of 2013 (n=178). Less than 60% of the vaccinated patients received 3 injections.
  
  
  CONCLUSIONS
  Implementation of the new recommendations was rapid but had only a slight impact on vaccination coverage.
authors.affiliation: Institut Curie-René-Huguenin, département d'oncologie chirurgicale, 35, rue Dailly, 92210 St-Cloud, France; Université Versailles-Saint-Quentin, équipe d'Accueil 7285, risques cliniques et sécurité en santé des femmes et en santé périnatale, 2, rue de la source de la Bièvre, 78180 Montigny-le-Bretonneux, France. Electronic address: delphine.hequet@gmail.com.
authors.forename: Delphine
authors.initials: D
authors.lastname: Héquet
authors.affiliation: Institut Curie-René-Huguenin, département d'oncologie chirurgicale, 35, rue Dailly, 92210 St-Cloud, France.
authors.forename: Nicolas
authors.initials: N
authors.lastname: Pouget
authors.affiliation: Institut Curie-René-Huguenin, département d'oncologie chirurgicale, 35, rue Dailly, 92210 St-Cloud, France.
authors.forename: Juan-Pablo
authors.initials: JP
authors.lastname: Estevez
authors.affiliation: Institut Curie, département de biostatistiques, 26, rue d'Ulm, 75005 Paris, France.
authors.forename: Mathieu
authors.initials: M
authors.lastname: Robain
authors.affiliation: Institut Curie-René-Huguenin, département d'oncologie chirurgicale, 35, rue Dailly, 92210 St-Cloud, France; Université Versailles-Saint-Quentin, équipe d'Accueil 7285, risques cliniques et sécurité en santé des femmes et en santé périnatale, 2, rue de la source de la Bièvre, 78180 Montigny-le-Bretonneux, France.
authors.forename: Roman
authors.initials: R
authors.lastname: Rouzier
mesh_terms: D000293:Adolescent; D000367:Age Factors; D002648:Child; D016208:Databases, Factual / Q000706:statistics & numerical data; D005260:Female; D005602:France; D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 / Q000008:administration & dosage / Q000600:supply & distribution; D006801:Humans; D017589:Immunization Programs / Q000706:statistics & numerical data / Q000639:trends; D009313:National Health Programs / Q000706:statistics & numerical data; D030361:Papillomavirus Infections / Q000150:complications / Q000517:prevention & control*; D053918:Papillomavirus Vaccines / Q000008:administration & dosage* / Q000600:supply & distribution; D002583:Uterine Cervical Neoplasms / Q000517:prevention & control* / Q000821:virology
chemical_list: D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; D053918:Papillomavirus Vaccines
keywords: Compliance; HPV; Vaccination; Vaccine